Next-generation KRAS G12C inhibitor improves survival in lung cancer
Phase 3 trial data show that the next-generation KRAS G12C inhibitor divarasib leads to longer progression-free survival than the first-generation inhibitors sotorasib and adagrasib in patients with non–small-cell lung cancer.